HemoGenyx Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of a suite of products to address current problems associated with the treatment of blood disorders such as cancers and autoimmune diseases, with bone marrow, or hematopoietic stem cell, transplants, and with viral infections. It operates through the United Kingdom and United States geographical segments. The company was founded by Alexis M. Sandler and Vladislav Sandler in 2012 and is headquartered in London, the United Kingdom.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company